Novel agents and evolving strategies in myelofibrotive neoplasm: an update from 2022 ASH annual conference

Andrew Wang; James Liu; Jeffrey J. Pu

doi:10.1186/s13045-023-01446-0

Novel agents and evolving strategies in myelofibrotive neoplasm: an update from 2022 ASH annual conference

Andrew Wang, James Liu, Jeffrey J. Pu

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Abstract

Myelofibrosis (MF) is a disorder characterized by the proliferation of myeloid precursors, commonly due to overactive JAK signaling. The discovery of the JAK2^V617F mutation and subsequent development of JAK inhibitors (JAKi) results in reduced spleen size, improved symptom, and enhanced survival in MF patients. However, there are unmet needs of additional novel targeted therapies for this incurable disease due to the limited utility of first-generation JAKis, which are associated with dose-limiting cytopenia and disease recurrence. New targeted treatment strategies for MF are on the horizon. We are here to discuss the latest clinical research findings presented in the 2022 ASH Annual Meeting.

Original language	English (US)
Article number	53
Journal	Journal of Hematology and Oncology
Volume	16
Issue number	1
DOIs	https://doi.org/10.1186/s13045-023-01446-0
State	Published - Dec 2023
Externally published	Yes

Keywords

Clinical research
Myelofibrotive neoplasm
Targeted therapy

ASJC Scopus subject areas

Hematology
Molecular Biology
Oncology
Cancer Research

Access to Document

10.1186/s13045-023-01446-0

Cite this

@article{e8838e68371b41d48b59b0beed971140,

title = "Novel agents and evolving strategies in myelofibrotive neoplasm: an update from 2022 ASH annual conference",

abstract = "Myelofibrosis (MF) is a disorder characterized by the proliferation of myeloid precursors, commonly due to overactive JAK signaling. The discovery of the JAK2V617F mutation and subsequent development of JAK inhibitors (JAKi) results in reduced spleen size, improved symptom, and enhanced survival in MF patients. However, there are unmet needs of additional novel targeted therapies for this incurable disease due to the limited utility of first-generation JAKis, which are associated with dose-limiting cytopenia and disease recurrence. New targeted treatment strategies for MF are on the horizon. We are here to discuss the latest clinical research findings presented in the 2022 ASH Annual Meeting.",

keywords = "Clinical research, Myelofibrotive neoplasm, Targeted therapy",

author = "Andrew Wang and James Liu and Pu, {Jeffrey J.}",

note = "Funding Information: The study is supported by: AA&MDSIF research grant to JJP (146818), American Cancer Society Grant to JJP (124171-IRG-13-043-02), NIH/NCI Grant to JJP (P30CA023074). Publisher Copyright: {\textcopyright} 2023, This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.",

year = "2023",

month = dec,

doi = "10.1186/s13045-023-01446-0",

language = "English (US)",

volume = "16",

journal = "Journal of Hematology and Oncology",

issn = "1756-8722",

publisher = "BioMed Central Ltd.",

number = "1",

}

TY - JOUR

T1 - Novel agents and evolving strategies in myelofibrotive neoplasm

T2 - an update from 2022 ASH annual conference

AU - Wang, Andrew

AU - Liu, James

AU - Pu, Jeffrey J.

N1 - Funding Information: The study is supported by: AA&MDSIF research grant to JJP (146818), American Cancer Society Grant to JJP (124171-IRG-13-043-02), NIH/NCI Grant to JJP (P30CA023074). Publisher Copyright: © 2023, This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.

PY - 2023/12

Y1 - 2023/12

N2 - Myelofibrosis (MF) is a disorder characterized by the proliferation of myeloid precursors, commonly due to overactive JAK signaling. The discovery of the JAK2V617F mutation and subsequent development of JAK inhibitors (JAKi) results in reduced spleen size, improved symptom, and enhanced survival in MF patients. However, there are unmet needs of additional novel targeted therapies for this incurable disease due to the limited utility of first-generation JAKis, which are associated with dose-limiting cytopenia and disease recurrence. New targeted treatment strategies for MF are on the horizon. We are here to discuss the latest clinical research findings presented in the 2022 ASH Annual Meeting.

AB - Myelofibrosis (MF) is a disorder characterized by the proliferation of myeloid precursors, commonly due to overactive JAK signaling. The discovery of the JAK2V617F mutation and subsequent development of JAK inhibitors (JAKi) results in reduced spleen size, improved symptom, and enhanced survival in MF patients. However, there are unmet needs of additional novel targeted therapies for this incurable disease due to the limited utility of first-generation JAKis, which are associated with dose-limiting cytopenia and disease recurrence. New targeted treatment strategies for MF are on the horizon. We are here to discuss the latest clinical research findings presented in the 2022 ASH Annual Meeting.

KW - Clinical research

KW - Myelofibrotive neoplasm

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85159194295&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85159194295&partnerID=8YFLogxK

U2 - 10.1186/s13045-023-01446-0

DO - 10.1186/s13045-023-01446-0

M3 - Letter

C2 - 37173704

AN - SCOPUS:85159194295

SN - 1756-8722

VL - 16

JO - Journal of Hematology and Oncology

JF - Journal of Hematology and Oncology

IS - 1

M1 - 53

ER -

Novel agents and evolving strategies in myelofibrotive neoplasm: an update from 2022 ASH annual conference

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this